Ochsner Clinic Foundation
- Type
- Teaching hospital
- Where
- New Orleans, LA
- Medicare CCN
- 190036
- Received
- $8,650,286 in 1,134 records, 2025 ($2,260,411 general, $6,389,874 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Ochsner Clinic Foundation Fuzzy (name and state)
- Business registration: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Business registration: OCHSNER CLINIC FOUNDATION INC. Fuzzy (name and state)
- Nonprofit contractor: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Plan sponsor: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Federal award recipient: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Federal award recipient: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Lobbying client: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Lobbying client: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Lobbying client: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Lobbying client: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Lobbying client: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Lobbying client: OCHSNER CLINIC FOUNDATION DBA OCHSNER HEALTH Fuzzy (name and state)
- Lobbying client: OCHSNER CLINIC FOUNDATION DBA OCHSNER HEALTH Fuzzy (name and state)
- Lobbying registrant: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Nonprofit: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Patent assignee: OCHSNER CLINIC FOUNDATION Fuzzy (name and state)
- Trademark owner: Ochsner Clinic Foundation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 224 | $2,260,411 |
| 2025 | Research payment | 910 | $6,389,874 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 910 | $6,389,874 |
| Grant | 56 | $1,432,427 |
| Space rental or facility fees (teaching hospital only) | 100 | $389,700 |
| Charitable Contribution | 4 | $175,500 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 25 | $124,290 |
| Long term medical supply or device loan | 13 | $98,006 |
| Education | 6 | $16,250 |
| Debt forgiveness | 16 | $12,488 |
| Gift | 3 | $10,000 |
| Consulting Fee | 1 | $1,750 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $34,811 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $12,916 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $11,215 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $10,951 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $8,433 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2025 |
| 2025-12-31 | Stryker Corporation | $1,629 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Stryker Corporation | $646 | Long term medical supply or device loan | In-kind items and services | SURGISTOOL Device, PATIENT HANDLING - PH | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $449 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2025 |
| 2025-12-31 | Stryker Corporation | $404 | Long term medical supply or device loan | In-kind items and services | SPY Device, ENDOSCOPY | 2025 | |
| 2025-12-31 | Stryker Corporation | $205 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Stryker Corporation | $68 | Long term medical supply or device loan | In-kind items and services | SPY Device, ENDOSCOPY | 2025 | |
| 2025-12-31 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-31 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-31 | Stryker Corporation | $42 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $4 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-30 | PFIZER INC. | $31,908 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-29 | Adaptive Biotechnologies Corporation | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-12-29 | Edwards Lifesciences Corporation | $400 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2025 | |
| 2025-12-29 | Janssen Research & Development, LLC | $351 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2025 |
| 2025-12-26 | MicroVention, Inc. | $1,500 | Research payment | Cash or cash equivalent | STENT Device, NEUROLOGICAL PRODUCT | FLOW RE-DIRECTION ENDOLUMINAL DEVICE X (FRED X) POST-APPROVAL STUDY | 2025 |
| 2025-12-26 | MicroVention, Inc. | $1,099 | Research payment | Cash or cash equivalent | STENT Device, NEUROLOGICAL PRODUCT | FLOW RE-DIRECTION ENDOLUMINAL DEVICE X (FRED X) POST-APPROVAL STUDY | 2025 |
| 2025-12-23 | Madrigal Pharmaceuticals | $3,719 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-12-23 | Coherus Oncology, Inc. | $1,600 | Research payment | Cash or cash equivalent | CHS11402 | 2025 | |
| 2025-12-23 | ABBVIE INC. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EMRELIS Drug, ONCOLOGY | 2025 | |
| 2025-12-22 | Genentech, Inc. | $16,120 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | 2025 |
| 2025-12-22 | Genentech, Inc. | $3,705 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | 2025 |
| 2025-12-22 | BeOne Medicines USA, Inc. | $2,331 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax | 2025 |
| 2025-12-19 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-19 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specificatio | 2025 |
| 2025-12-19 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specificatio | 2025 |
| 2025-12-18 | Stryker Corporation | $9,225 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NA Device, CRANIOMAXILLOFACIAL | 2025 | |
| 2025-12-18 | Medical Device Business Services, Inc. | $3,550 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | La Jolla Pharmaceutical Company | $500 | Research payment | Cash or cash equivalent | XACDURO Drug, INFECTIOUS DISEASE | A SINGLE-ARM, OPEN-LABEL, PROSPECTIVE, OBSERVATIONAL STUDY TO ASSESS THE SAFETY OF SULBACTAM-DURLOBACTAM, INCLUDING THE | 2025 |
| 2025-12-18 | Alnylam Pharmaceuticals Inc. | $50 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-18 | Alnylam Pharmaceuticals Inc. | $25 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-16 | Gilead Sciences, Inc. | $120,832 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-16 | Boston Scientific Corporation | $7,560 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-12-16 | PFIZER INC. | $7,500 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY V | 2025 |
| 2025-12-16 | Edwards Lifesciences Corporation | $5,050 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-12-16 | JAZZ PHARMACEUTICALS INC. | $2,000 | Research payment | Cash or cash equivalent | Modeyso Drug, HEMATOLOGY/ONCOLOGY | ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Random | 2025 |
| 2025-12-11 | Genmab U.S., Inc. | $1,000 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2025 |
| 2025-12-10 | Mannkind Corporation | $6,500 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | $3,675 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | $1,659 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | $237 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-09 | Merck Sharp & Dohme LLC | $397,600 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1, First-in-Human Study of NTX 1088, a Monoclonal Antibody Targeting the Poliovirus Receptor PVR, as Monotherapy | 2025 |
| 2025-12-09 | Gilead Sciences, Inc. | $155,154 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-09 | Mannkind Corporation | $10,543 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-12-09 | Mannkind Corporation | $4,980 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-12-08 | BeOne Medicines USA, Inc. | $1,000 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax | 2025 |
| 2025-12-05 | Eli Lilly and Company | $24,500 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS | 2025 | |
| 2025-12-05 | Madrigal Pharmaceuticals | $21,997 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-12-05 | Medtronic, Inc. | $4,751 | Research payment | Cash or cash equivalent | INTERSTIM Device, Sacral Nerve Stimulation | PSR-SNM | 2025 |
| 2025-12-04 | Coherus Oncology, Inc. | $21,390 | Research payment | Cash or cash equivalent | CHS11402 | 2025 | |
| 2025-12-04 | Genentech, Inc. | $19,707 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | 2025 |
| 2025-12-04 | Genentech, Inc. | $3,586 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | 2025 |
| 2025-12-04 | Alnylam Pharmaceuticals Inc. | $948 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $13,804 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $13,804 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $13,426 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $13,426 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $13,426 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $11,677 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $11,677 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $11,677 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $2,848 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $2,614 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $2,614 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $2,614 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $1,688 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $1,688 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $1,210 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $1,210 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-02 | GENZYME CORPORATION | $9,884 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 | |
| 2025-12-01 | Stryker Corporation | $3,975 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MAKO Device, KNEES, HIPS | 2025 | |
| 2025-11-29 | Madrigal Pharmaceuticals | $1,500 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-11-27 | PFIZER INC. | $18,131 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-11-27 | UCB SA | $9,600 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2025 | |
| 2025-11-27 | Abbott Laboratories | $3,500 | Research payment | Cash or cash equivalent | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-11-26 | Edwards Lifesciences Corporation | $150,000 | Charitable Contribution | Cash or cash equivalent | 2025 | ||
| 2025-11-26 | PFIZER INC. | $18 | Research payment | In-kind items and services | A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 C | 2025 | |
| 2025-11-25 | Boston Scientific Corporation | $800 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_NMD | IMPROVE | 2025 |
| 2025-11-24 | BeOne Medicines USA, Inc. | $3,738 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax | 2025 |
| 2025-11-24 | BeOne Medicines USA, Inc. | $3,250 | Research payment | Cash or cash equivalent | TEVIMBRA Drug, Oncology | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combina | 2025 |
| 2025-11-24 | Ferring Pharmaceuticals AS | $1,000 | Research payment | Cash or cash equivalent | REBYOTA Biological, GASTROENTEROLOGY | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational | 2025 |
| 2025-11-24 | Ferring Pharmaceuticals AS | $175 | Research payment | Cash or cash equivalent | REBYOTA Biological, GASTROENTEROLOGY | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational | 2025 |
| 2025-11-21 | Janssen Research & Development, LLC | $8,149 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-11-21 | E.R. Squibb & Sons, L.L.C. | $1,450 | Research payment | Cash or cash equivalent | A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatmen | 2025 | |
| 2025-11-20 | PFIZER INC. | $4,500 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-11-20 | Madrigal Pharmaceuticals | $4,000 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-11-20 | Sumitomo Pharma America, Inc. | $2,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-11-20 | Roche Products Limited | $1,500 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2025 |
| 2025-11-20 | Madrigal Pharmaceuticals | $405 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-11-20 | Roche Products Limited | $253 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2025 |
| 2025-11-18 | Boston Scientific Corporation | $13,452 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-11-18 | Boston Scientific Corporation | $3,478 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | ADVENT PAS | 2025 |
| 2025-11-17 | PFIZER INC. | $51,487 | Research payment | Cash or cash equivalent | ZAVZPRET Drug, PAIN | THE EVALUATION OF AN URGENT CARE MIGRAINE MANAGEMENT PATHWAY | 2025 |
| 2025-11-17 | Genentech, Inc. | $6,500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | 2025 |
| 2025-11-17 | SANOFI US SERVICES INC. | $3,640 | Research payment | Cash or cash equivalent | A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refra | 2025 | |
| 2025-11-17 | GENZYME CORPORATION | $500 | Research payment | Cash or cash equivalent | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 | |
| 2025-11-16 | PFIZER INC. | $2,750 | Research payment | In-kind items and services | A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 C | 2025 | |
| 2025-11-15 | Novartis Pharmaceuticals Corporation | $26 | Research payment | In-kind items and services | Fabhalta Drug, Immunology | An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial t | 2025 |
| 2025-11-14 | Stryker Corporation | $2,950 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACCOLADE Device, HIPS | 2025 | |
| 2025-11-13 | Gilead Sciences, Inc. | $4,063 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-11-13 | La Jolla Pharmaceutical Company | $3,119 | Research payment | Cash or cash equivalent | XACDURO Drug, INFECTIOUS DISEASE | A SINGLE-ARM, OPEN-LABEL, PROSPECTIVE, OBSERVATIONAL STUDY TO ASSESS THE SAFETY OF SULBACTAM-DURLOBACTAM, INCLUDING THE | 2025 |
| 2025-11-13 | Exelixis Inc. | $2,500 | Research payment | Cash or cash equivalent | Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors | 2025 | |
| 2025-11-13 | Exelixis Inc. | $2,000 | Research payment | Cash or cash equivalent | Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors | 2025 | |
| 2025-11-13 | Exelixis Inc. | $1,500 | Research payment | Cash or cash equivalent | Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors | 2025 | |
| 2025-11-13 | Gilead Sciences, Inc. | $500 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-11-12 | Gilead Sciences, Inc. | $51,356 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-12 | Gilead Sciences, Inc. | $4,500 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-11-12 | Gilead Sciences, Inc. | $2,000 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-11-11 | Novartis Pharmaceuticals Corporation | $65,420 | Research payment | In-kind items and services | Rhapsido Drug, Immunology | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 |
| 2025-11-11 | PROGENICS PHARMACEUTICALS, INC. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | 2025 | |
| 2025-11-11 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM | 2025 |
| 2025-11-07 | Exelixis Inc. | $9,871 | Research payment | Cash or cash equivalent | Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors | 2025 | |
| 2025-11-07 | BIOTISSUE HOLDINGS INC. | $4,000 | Research payment | Cash or cash equivalent | TTAX01-CR006 | 2025 | |
| 2025-11-06 | JAZZ PHARMACEUTICALS INC. | $3,897 | Research payment | Cash or cash equivalent | ZIIHERA Drug, HEMATOLOGY/ONCOLOGY | A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Aga | 2025 |
| 2025-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2025 |
| 2025-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | $965 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2025 |
| 2025-11-06 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-11-06 | Alnylam Pharmaceuticals Inc. | $316 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-06 | Alnylam Pharmaceuticals Inc. | $50 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-04 | Gilead Sciences, Inc. | $101,971 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-04 | Madrigal Pharmaceuticals | $3,000 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-11-04 | Madrigal Pharmaceuticals | $1,500 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-11-04 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | AGENT IDE | 2025 |
| 2025-11-03 | Abbott Laboratories | $65,329 | Research payment | Cash or cash equivalent | NAVITOR Device, Structural Heart | NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2025 |
| 2025-11-03 | Corcym Inc | $4,413 | Research payment | Cash or cash equivalent | CARBOMEDICS CARBO-SEAL VALSALVA Device, CARDIAC SURGERY | MANTRA | 2025 |
| 2025-11-03 | Corcym Inc | $3,279 | Research payment | Cash or cash equivalent | CARBOMEDICS CARBO-SEAL VALSALVA Device, CARDIAC SURGERY | MANTRA | 2025 |
| 2025-11-03 | Corcym Inc | $2,500 | Research payment | Cash or cash equivalent | CARBOMEDICS CARBO-SEAL VALSALVA Device, CARDIAC SURGERY | MANTRA | 2025 |
| 2025-11-03 | Corcym Inc | $2,500 | Research payment | Cash or cash equivalent | CARBOMEDICS CARBO-SEAL VALSALVA Device, CARDIAC SURGERY | MANTRA | 2025 |
| 2025-11-03 | Corcym Inc | $1,000 | Research payment | Cash or cash equivalent | CARBOMEDICS CARBO-SEAL VALSALVA Device, CARDIAC SURGERY | MANTRA | 2025 |
| 2025-11-03 | Corcym Inc | $560 | Research payment | Cash or cash equivalent | CARBOMEDICS CARBO-SEAL VALSALVA Device, CARDIAC SURGERY | MANTRA | 2025 |
| 2025-11-01 | PFIZER INC. | $16,746 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-10-31 | Alexion Pharmaceuticals, Inc. | $21,500 | Research payment | Cash or cash equivalent | a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult p | 2025 | |
| 2025-10-31 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-31 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-30 | ARRAY BIOPHARMA INC | $20,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-30 | Edwards Lifesciences Corporation | $3,103 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2025 | |
| 2025-10-29 | Abbott Laboratories | $2,205 | Research payment | Cash or cash equivalent | TACTICATH ABLATION CATHETER, SENSOR ENABLED Device, Structural Heart | NCT05434650--Abbott Atrial Fibrillation Post Approval Study | 2025 |
| 2025-10-28 | Boston Scientific Corporation | $14,954 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ROWAN | 2025 |
| 2025-10-28 | ABBVIE INC. | $1,000 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have | 2025 |
| 2025-10-28 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-28 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-27 | Regeneron Pharmaceuticals, Inc. | $14,500 | Research payment | Cash or cash equivalent | VEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of | 2025 |
| 2025-10-27 | GENZYME CORPORATION | $5,453 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 | |
| 2025-10-27 | Regeneron Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | VEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of | 2025 |
| 2025-10-27 | Regeneron Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | VEOPOZ Biological, OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of | 2025 |
| 2025-10-27 | BeOne Medicines USA, Inc. | $1,005 | Research payment | Cash or cash equivalent | TEVIMBRA Drug, Oncology | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combina | 2025 |
| 2025-10-24 | Vericel Corporation | $13,750 | Grant | Cash or cash equivalent | MACI Biological, Orthopedics | 2025 | |
| 2025-10-23 | Mannkind Corporation | $1,600 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-10-23 | Genentech, Inc. | $1,430 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | 2025 |
| 2025-10-23 | Genentech, Inc. | $800 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | 2025 |
| 2025-10-23 | Edwards Lifesciences Corporation | $667 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2025 | |
| 2025-10-23 | Mannkind Corporation | $385 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-10-22 | Intercept Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | 2025 | |
| 2025-10-22 | Abbott Laboratories | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROCLAIM Device, Structural Heart | 2025 | |
| 2025-10-21 | La Jolla Pharmaceutical Company | $10,250 | Research payment | Cash or cash equivalent | XACDURO Drug, INFECTIOUS DISEASE | A SINGLE-ARM, OPEN-LABEL, PROSPECTIVE, OBSERVATIONAL STUDY TO ASSESS THE SAFETY OF SULBACTAM-DURLOBACTAM, INCLUDING THE | 2025 |
| 2025-10-21 | La Jolla Pharmaceutical Company | $3,500 | Research payment | Cash or cash equivalent | XACDURO Drug, INFECTIOUS DISEASE | A SINGLE-ARM, OPEN-LABEL, PROSPECTIVE, OBSERVATIONAL STUDY TO ASSESS THE SAFETY OF SULBACTAM-DURLOBACTAM, INCLUDING THE | 2025 |
| 2025-10-20 | GENZYME CORPORATION | $12,500 | Research payment | Cash or cash equivalent | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 | |
| 2025-10-17 | Genentech, Inc. | $64,019 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | 2025 |
| 2025-10-17 | KARL STORZ Endoscopy-America | $2,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-10-17 | National Marrow Donor Program | $1,545 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-17 | Intercept Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | 2025 | |
| 2025-10-17 | Madrigal Pharmaceuticals | $405 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-10-17 | National Marrow Donor Program | $330 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-17 | Madrigal Pharmaceuticals | $288 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-16 | Alnylam Pharmaceuticals Inc. | $15,441 | Research payment | Cash or cash equivalent | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 |
The latest 200 records of 1,134.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New Orleans, LA, county Orleans Parish, LA, state Louisiana; placed by its city name.
| Measure | Place (city or town) New Orleans, LA | County Orleans Parish, LA | State Louisiana |
|---|---|---|---|
| Population B01003 | 371,853 | 371,853 | 4,611,961 |
| Population, 2020 census P1 | 383,997 | 383,997 | 4,657,757 |
| Median age B01002 | 38.8 | 38.8 | 38.0 |
| Under 18 B01001 | 19.7% | 19.7% | 23.5% |
| 65 and over B01001 | 17.2% | 17.2% | 16.7% |
| Households B11001 | 155,821 | 155,821 | 1,804,780 |
| Foreign born B05002 | 6.6% | 6.6% | 4.9% |
| Median household income B19013 | $56,631 | $56,631 | $60,756 |
| Median family income B19113 | $80,929 | $80,929 | $79,407 |
| Per capita income B19301 | $40,662 | $40,662 | $35,038 |
| Poverty rate B17001 | 22.6% | 22.6% | 18.9% |
| Unemployment rate B23025 | 7.5% | 7.5% | 6.3% |
| Civilian labor force B23025 | 184,482 | 184,482 | 2,148,164 |
| Mean commute (minutes) B08013 | 22.6 | 22.6 | 25.7 |
| Bachelor's degree or higher B15003 | 42.4% | 42.4% | 27.0% |
| Housing units B25001 | 195,552 | 195,552 | 2,108,902 |
| Owner-occupied B25003 | 51.2% | 51.2% | 67.4% |
| Renters B25003 | 48.8% | 48.8% | 32.6% |
| Median home value B25077 | $315,700 | $315,700 | $216,500 |
| Median gross rent B25064 | $1,251 | $1,251 | $1,064 |
| White, not Hispanic B03002 | 30.1% | 30.1% | 55.7% |
| Black B03002 | 53.9% | 53.9% | 30.5% |
| Hispanic or Latino B03002 | 8.2% | 8.2% | 7.2% |
| Asian B03002 | 2.8% | 2.8% | 1.7% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.4% |
Economy now FRED unemployment 4.0% in Sep 2026 (4.2% a year earlier); per capita personal income $64,103 in 2025, up 28% in five years (+2.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Orleans, LA.
Comments